Table 1.
Baseline characteristics of included patients.
| Total N = 104 | |
|---|---|
| Age, median (years) | 18.0 (11.8–30.0) |
| Sex, male | 71 (68.3) |
| CL (Treatment) history | |
| Referred from other health facility | 85 (81.7) |
| Previous CL episode (n = 103) | 6 (5.8) |
| Traditional treatment used | 74 (71.1) |
| Herbal | 64 (61.5) |
| Holy water | 12 (11.5) |
| Burning | 1 (0.9) |
| Other | 3 (2.9) |
| Modern treatment (any) a | 40 (38.5) |
| CL-specific treatment | 6 (5.8) |
| Lesion characteristics | |
| Duration in months, median (IQR) | 11.5 (7.0–17.0) |
| Type of lesion | |
| LCL | 30 (28.8) |
| MCL | 69 (66.3) |
| DCL | 5 (4.8) |
| No. of active lesions | |
| 1 | 70 (67.3) |
| 2 | 16 (15.4) |
| 3 | 10 (9.6) |
| ≥4 | 8 (7.7) |
| Presence of concomitant CL scar | 5 (4.8) |
| Size (largest diameter), median IQR (n = 100) | 5.0 (4.0–8.0) |
| Location of index lesion | |
| Face | 90 (86.5) |
| Arm/hand | 10 (9.6) |
| Other body part | 4 (3.8) |
| Index lesion presentation | |
| Plaque | 98 (94.2) |
| Scaly | 62 (59.6) |
| Crusted | 55 (52.9) |
| Papular | 54 (51.9) |
| Erythematous | 35 (33.7) |
| Hyperpigmented | 31 (28.9) |
| Swollen | 22 (21.2) |
| Nodular | 21 (20.2) |
| Ulcerated | 18 (17.3) |
CL: cutaneous leishmaniasis, DCL: diffuse cutaneous leishmaniasis, IQR: interquartile range, LCL: localized cutaneous leishmaniasis, MCL: mucocutaneous leishmaniasis. a Any ointment, tablets, syrup, or injection received at a health post, health center, hospital, or pharmacy In cases of missing data, the total patients with available data are indicated with (n = x) behind the respective variable.